Sorafenib tosylate CAS 475207-59-1 for the treatment of advanced liver cancer

Basic Views

Product Name: Sorafenib tosylate 

Synonyms: SORAFENIB TOSYLATE;Sorafenib & its intermediates;Sorafinib mesylate;4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide monomethanesulfonate;Sorafenib Tosylate(Bay 43-9006,Nexavar);2-PyridinecarboxaMide, 4-[4-[[[[4-chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]phenoxy]-N-Methyl-, 4-Methylbenzenesulfonate;Sorafenib Tosylate (Nexavar);Sorafenib (Nexavar) 

CAS: 475207-59-1 

MF: C21H16ClF3N4O3.C7H8SO3 

MW: 637.03 

Product Categories: Bay 43-9006;Inhibitors 

Mol File: Mol File 

Usage: for the treatment of advanced liver cancer. 

Appearance:white powder

Purity:99%

Package: 25kg/barrel or as your inquiry 

Shelf life:2 years

Standard:Enterprise Standard 

Price:negotiable 

MOQ:10g

Specification:ISO9001,USP,BP

Trade Mark:CQSP

Port:Shenzhen/Shanghai,China

Production Capacity:5000kg/month

Shipping: FedEx, DHL, EMS, TNT, HK EMS, Eub, Etk

Payment: Western Union, Moneygram, T/T, Bitcoin

Delivery time: Parcel can be sent out within 24 hours after payment,4-7days to arrive.

More details pls contact:Whatapp:86 13048470428  

 Skype/E-mail : summer at chembj.com

Introduction of Toluenesulfonic Sorafenib

Toluenesulfonic Sorafenib is a kind of novel multi-targeted anticancer drug and was first successfully developed by the German pharmaceutical company Bayer. It can simultaneously take effect on both the tumor cell and tumor vasculature. It has a dual anti-tumor effect: not only by blocking the RAF/MEK/ERK-mediated cell signaling pathway for direct inhibition of tumor cell proliferation, but also by inhibiting VEGF and platelet-derived growth factor (PDGF) receptor for blocking tumor angiogenesis and indirectly inhibition of the growth of tumor cells. 

It has shown a wide range of anti-tumor activity in preclinical animal studies. In phase III randomized clinical studies for treating patients with advanced kidney cancer in Europe and the United States, 903 cases of patients who had gotten failure upon receiving a systemic therapy (chemotherapy or immune) before for advanced kidney cancer randomly divided into two groups, one group received treatment of toluenesulfonic Sorafenib (referred Sorafenib), the other group received a placebo. 222 cases of deaths have occurred upon the interim analysis with the results showing that the objective effectiveness rate of two groups was 10% and 2%, respectively, and with 74% and 53% of patients, respectively, having their tumor remained stable. 

Indications and usage

1, the treatment of advanced renal cell carcinoma can not be surgery.

2, the treatment of non-surgical or distant metastasis of primary hepatocellular carcinoma.

There is a lack of randomized controlled clinical data comparing sorafenib with interventional therapy, such as transcatheter arterial chemoembolization (TACE), in patients with advanced hepatocellular carcinoma, so it is not clear whether the drug is superior to or inferior to interventional therapy. After receiving interventional therapy in patients with sorafenib is beneficial, it is recommended that doctors consider based on the specific circumstances of patients, select the appropriate treatment.

Dosage and Usage

Recommended dosage of sorafenib 0.4g (2 × 0.2g), twice daily, fasting or with low-fat, medium fat diet.

Methods of administration

Oral, to a cup of warm water swallow.